Monopolize Clinical Validation Dataset via Resource Data Consortium

Intel / Context Summary

NASA holds nearly 50 patented and patent-pending technologies from the Robonaut 2 program specifically positioned for medical applications, with established licensing infrastructure but zero documented market demand signals. The agency has supply-side readiness through its Technology Transfer Program but lacks commercial validation and market pull evidence.

Catalyst: Why Now

NASA's technologies have space validation but zero clinical validation data for medical applications, creating a critical gap that medical device companies need for FDA submissions but cannot generate themselves without access to the IP.

Friction: The Bottleneck

• Vulnerability: NASA's technologies have space validation but zero clinical validation data for medical applications, creating a critical gap that medical device companies need for FDA submissions but cannot generate themselves without access to the IP.
• Capital yield: $750k-$1M annual recurring revenue from dataset subscriptions
• Resource capture: Proprietary clinical validation dataset for NASA robotics in medical applications (500+ hours, 3 study types)
• Influence capture: De facto 'gold standard' authority for medical robotics performance metrics
• Sovereignty yield: Exclusive commercial licensing rights to clinical validation data required for FDA submissions
• Required vectors: Vector: Clinical Research Design, Vector: Data Science & Analytics, Vector: Healthcare Institutional Partnerships, Vector: FDA Regulatory Strategy

Wedge: Execution Protocol

Phase 1: Hospital Research Partnership Identification & Regulatory Gap Analysis: Scrape clinicaltrials.gov for all robotic surgery studies at top 20 US research hospitals. Cross-reference with NIH grant database for robotics funding. Identify 5 hospitals with active IRB-approved robotics research but no NASA partnership. Map FDA Class II device regulatory requirements for precision metrics documentation. → Phase 2: Form Medical Robotics Benchmarking Consortium & Secure NASA IP Access: Draft consortium agreement establishing proprietary data ownership structure. Submit non-exclusive NASA license application for 5 core sensing/control patents. Negotiate with hospitals: they get free access to NASA technology for research; consortium owns all resulting clinical data. Secure $100k seed funding from medtech VC for initial study costs. → Phase 3: Execute Clinical Validation Studies & Data Capture: Design 3 standardized clinical studies: (1) robotic suture precision vs. human surgeons, (2) tremor reduction in microsurgical applications, (3) haptic feedback accuracy metrics. Execute at partner hospitals with IRB oversight. Capture all raw sensor data, video recordings, and clinical outcome metrics into proprietary database. → Phase 4: Monetize Dataset Through Subscription & Licensing: Create tiered data access model: $50k/year for full dataset access, $15k for specific study reports, $5k for regulatory submission packages. Target 100 medical device companies from FDA 510(k) database. Position dataset as 'gold standard' for FDA robotic device submissions.

Routing Vectors

Specific Roles Required

Claim Protocol